Human trial ledger

Oral NMN in human trials

Here the refill story meets human measurements. Two trials offer specific results; a wider review leaves the larger clinical claim open.

Insulin sensitivity after oral NMN

The trial in prediabetic, postmenopausal women reported improved muscle insulin sensitivity after 10 weeks of oral NMN. Insulin sensitivity describes how readily tissue responds to insulin. The study assessed it with a hyperinsulinemic-euglycemic clamp, a controlled test of that response, and reported changes in insulin signalling.

The same trial reports no change in body composition or HbA1c. Those outcomes matter alongside the favourable result. A measurable improvement in muscle insulin sensitivity can coexist with unchanged measurements elsewhere.

I respect this particular result for its specific population and test; the broad phrase “metabolic support” gives me far less to work with. My enthusiasm stays with the measured response in these women. An IV claim would have to establish its own intervention and outcome.

Walking distance and quality of life

The multicentre, double-blind trial in healthy middle-aged adults studied oral NMN for 60 days. Blood NAD+ rose in a dose-dependent fashion. Walking distance and quality-of-life scores improved compared with placebo. These are the study's reported outcomes; the duration describes the experiment.

I take more interest in a walking outcome than in a blood value alone. It is also a reminder that a functional test and a questionnaire ask different questions, even when both favour the same study group.

The experiment used oral NMN. I would be stretching the result if I presented its walking outcome as something already established for intravenous NAD+. Its value here is the example of a human outcome being measured alongside the biochemical change.

Walking shoes sit beside an empty indoor course marked with plain floor strips. — Editorial illustration of a generic walking course; the oral NMN trial reported walking distance, but this is no reconstruction of its testing room.

The wider human record

The 2025 narrative review of NAD+ precursor supplementation in human ageing concludes that clinical efficacy has been limited. Blood NAD+ elevation is consistent, while translation into clinical endpoints is inconsistent. The review also describes sparse information about tissue-specific NAD+ dynamics.

Connecting those measurements looks like the most important unfinished task to me. It leaves room for an interesting result in a defined population and resists turning that result into an answer for everyone. Both trials above can matter without making a general rejuvenation claim credible.

I favour a follow-up that repeats the useful outcome in a well-defined population and examines the relevant tissue. More detail about where replenishment occurs would make the story stronger than a larger number in an isolated blood test.

Questions for the next experiment

The muscle trial’s combination of improved insulin sensitivity and unchanged body composition and HbA1c gives the next experiment a concrete starting point. Which changes persist? Which populations show them again? How do the tissue measurements relate to the functional result?

Those are research questions. No personal dose or schedule follows from them. The studies here used oral NMN, and the IV record contains other compounds, models and comparisons. I prefer a replenishment story that can name those boundaries and still remain curious.